SCS Traditional denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for scs traditional are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana May Deny Traditional SCS as Not FDA-Approved

A "not FDA-approved" denial for traditional spinal cord stimulation is almost always a classification or documentation error rather than an accurate regulatory finding. Traditional SCS devices have been subject to FDA premarket review — either 510(k) clearance or Premarket Approval (PMA) — for decades, covering established indications including chronic intractable pain of the trunk and limbs and failed back surgery syndrome. This denial type typically arises when (a) the specific device model is newer and the reviewer did not locate its clearance, (b) the submitted diagnosis code reflects an off-label use that falls outside the cleared indication as described in the device labeling, or (c) the denial was issued in error based on an incomplete record review.

## Why This Denial Is Directly Rebuttable

The correction is documentary: provide Humana with the FDA clearance or approval document for the exact device model, confirm that the proposed use matches the cleared indication, and request that the denial be rescinded as factually unsupported. If the use is technically off-label, the appeal shifts to a medical-necessity argument — off-label use of a cleared device is not the same as use of a non-approved device, and Humana's own coverage policy likely addresses this distinction.

## Your Federal Appeal Rights

• Internal appeal: File immediately under ERISA §503 or Humana's grievance procedures, attaching the FDA clearance documentation as exhibit A. This category of denial often resolves at the internal level when the correct documentation is provided.
• External review (ACA §2719): If the internal appeal is unsuccessful, this adverse determination is eligible for binding independent external review. The window is generally up to four months from the denial notice.
• Expedited review: Request if your implant schedule is time-sensitive.

## Documentation to Gather

1. FDA 510(k) clearance or PMA approval — obtain the specific clearance document for the SCS device model being implanted from the FDA's publicly searchable 510(k) and PMA databases (accessible at fda.gov). Confirm the cleared indication matches your diagnosis. 2. Device labeling (IFU) — the FDA-approved Instructions for Use, which states the indications, contraindications, and intended patient population. 3. Prescriber letter — a statement from the implanting physician confirming that the proposed use falls within the FDA-cleared indication as described in the device labeling. 4. Denial letter analysis — identify the specific provision cited; if it references an approval requirement, confirm whether the plan means FDA approval/clearance for the device or FDA approval of an accompanying drug (not applicable to SCS hardware). 5. Humana coverage policy — obtain the SCS policy and confirm that the device's FDA-cleared status satisfies the policy's coverage prerequisites.

## Criteria-Mapping Approach

Lead your appeal with a one-page executive summary: the denial claimed the device is not FDA-approved; the attached FDA document (Exhibit A) shows clearance date, cleared indication, and device model. Then map the cleared indication to your diagnosis and the treating physician's clinical plan. Keep the argument narrow and factual — this type of denial does not require extensive clinical narrative; it requires clean documentation.